钠-葡萄糖共转运蛋白2抑制剂联合利拉鲁肽对2型糖尿病患者临床疗效及纤溶酶原激活物抑制物-1和胱抑素C水平的影响  

Effects of sodium-glucose cotransporter 2 inhibitor combined with liraglutide on clinical efficacy and levels of plasminogen activator inhibitor-1 and cystatin C in patients with type 2 diabetes mellitus

作　　者：周志云 徐平平 邓红苗 ZHOU Zhiyun;XU Pingping;DENG Hongmiao(Department of Pharmacy,Yingtan People's Hospital,Yingtan,Jiangxi,335000,China)

机构地区：[1]鹰潭市人民医院药学室,江西鹰潭335000

出　　处：《当代医学》2024年第23期25-29,共5页Contemporary Medicine

摘　　要：目的探究钠-葡萄糖共转运蛋白2(sodium-glucose cotransporter 2,SGLT2)抑制剂联合利拉鲁肽对2型糖尿病(type 2 diabetes mellitus,T2DM)患者的临床疗效及对纤溶酶原激活物抑制物-1(plasminogen activator inhibitor-1,PAI-1)、胱抑素C(cystatin C,CysC)水平的影响。方法选取2021年11月至2022年11月鹰潭市人民医院收治的70例T2DM患者作为研究对象,按照随机数字表法分为对照组与实验组,每组35例。对照组予以利拉鲁肽治疗,实验组在对照组基础上加用SGLT-2抑制剂治疗。比较两组治疗前后炎症因子[肿瘤坏死因子-α(tumor necrosis factorɑ,TNF-α)、超敏C反应蛋白(hypersensitive C-reactive protein,hs-CRP)、白细胞介素-6(interleukin-6,IL-6)]、糖代谢相关指标[餐后2 h血糖(postprandial 2 h blood glucose,2 h PBG)、糖化血红蛋白(glycosylated hemoglobin,HbA1c)、空腹血糖(fasting blood glucose,FBG)]、其他生化指标[纤溶酶原激活物抑制物-1(plasminogen activator inhibitor-1,PAI-1)、胱抑素C(cystatin C,CysC)水平]、生命质量评分、临床疗效及不良反应发生情况。结果治疗后,两组TNF-α、hs-CRP、IL-6、2 h PBG、FBG、HbA1c、PAI-1、CysC水平均低于治疗前,且实验组低于对照组,差异有统计学意义(P<0.05)。治疗后,两组总体健康、心理健康、活力、躯体功能评分均高于治疗前,且实验组高于对照组,差异有统计学意义(P<0.05)。实验组治疗总有效率为97.14%,高于对照组的80.00%,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论SGLT-2抑制剂联合利拉鲁肽治疗T2DM疗效更佳,可减轻机体炎症反应,控制血糖,降低PAI-1、CysC水平,并提高患者的生命质量,且安全性较高。Objective To explore the effects of sodium-glucose cotransporter 2(SGLT-2)inhibitor combined with liraglutide clinical efficacy and levels of plasminogen activator inhibitor-1(PAI-1)and cystatin C(CysC)in patients with 2 diabetes mellitus(T2DM).Methods A total of 70 T2DM patients admitted to Yingtan People's Hospital from November 2021 to November 2022 were selected as the study subjects,and they were divided into the control group and experimental group according to random number table method,with 35 cases in each group.The control group was treated with liraglutide,and the experimental group was treated with SGLT-2 inhibitor based on the control group.The inflammatory factor(tumor necrosis factor-α[TNF-α],hypersensitive C-reactive protein[hs-CRP],interleukin-6[IL-6]),related indexes of glucose metabolism(postprandial 2 h blood glucose[2 h PBG],glycosylated hemoglobin A1c[HbA1c],fasting blood glucose[FBG]),other biochemical parameters(plasminogen activator inhibitor-1[PAI-1],cystatin C[CysC]),quality of life score before and after treatment,clinical efficacy,and adverse events were compared between the two groups.Results After treatment,the levels of TNF-α,hs-CRP,IL-6,2 h PBG,FBG,HbA1c,PAI-1 and CysC of the two groups were lower than before treatment,and the experimental group was lower than the control group,and the differences were statistically significant(P<0.05).After treatment,the scores of overall health,mental health,vitality and physical function of the two groups were higher than those before treatment,and the experimental group was higher than the control group,and the differences were statistically significant(P<0.05).The total effective rate in the experimental group was 97.14%,which was higher than 80.00%in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups.Conclusion SGLT-2 inhibitor combined with liraglutide has better efficacy in the treatment of T2DM,which can reduce

关 键 词：钠-葡萄糖共转运蛋白2抑制剂 利拉鲁肽 纤溶酶原激活物抑制物-1 胱抑素C 

分 类 号：R58[医药卫生—内分泌]